Empowered Funds LLC acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 8,710 shares of the company's stock, valued at approximately $388,000.
Other hedge funds have also recently made changes to their positions in the company. Creative Planning boosted its position in shares of Omnicell by 23.1% during the third quarter. Creative Planning now owns 11,667 shares of the company's stock worth $509,000 after acquiring an additional 2,188 shares during the last quarter. Everence Capital Management Inc. bought a new position in shares of Omnicell during the 3rd quarter valued at about $249,000. Roubaix Capital LLC bought a new position in shares of Omnicell during the 3rd quarter valued at about $1,851,000. 1620 Investment Advisors Inc. grew its position in shares of Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock valued at $96,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Rice Hall James & Associates LLC bought a new stake in shares of Omnicell in the third quarter worth about $2,723,000. Institutional investors own 97.70% of the company's stock.
Insider Buying and Selling
In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares of the company's stock, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.64% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Several equities analysts have weighed in on the company. JPMorgan Chase & Co. raised their price target on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a report on Thursday, November 21st. Barclays upped their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. Bank of America dropped their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Finally, Benchmark reaffirmed a "buy" rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $52.33.
View Our Latest Stock Analysis on OMCL
Omnicell Stock Up 0.2 %
Shares of OMCL stock traded up $0.07 during mid-day trading on Friday, hitting $39.72. The stock had a trading volume of 429,368 shares, compared to its average volume of 434,289. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The firm's 50-day moving average is $43.09 and its two-hundred day moving average is $43.85. The firm has a market capitalization of $1.84 billion, a P/E ratio of 147.12, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.
Omnicell Profile
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Further Reading
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
